Welcome to the Grohar Laboratory

The goal of the Grohar Lab is to develop and clinically translate novel small molecule therapies for the treatment of Ewing sarcoma.  Ewing sarcoma absolutely depends on the EWS-FLI1 transcription factor for cell survival. Unfortunately, there are no effective small molecule EWS-FLI1 inhibitors currently in use in the clinic.  EWS-FLI1 is a challenging drug target because it is a transcription factor.  Therefore, we employ a variety of complementary methods to identify and clinically translate novel EWS-FLI1 targeted therapies.  These methods include:

  • High Throughput Drug Screening
  • siRNA screening
  • Molecular Pharmacology
  • Cancer Biology
  • Chemical Biology

Our goal is to identify novel small molecule EWS-FLI1 inhibitors, employ analog based optimization, understand the mechanism of action of these small molecules and translate these therapies to the clinic.  In addition, we are working to develop a number of novel EWS-FLI1 directed combination therapies.  In the process, we hope to understand transcription factor drug targeting and apply this understanding to a variety of other tumors.